Literature DB >> 29093431

Increased Prognostic Value of Query Amyloid Late Enhancement Score in Light-Chain Cardiac Amyloidosis.

Ke Wan1, Jiayu Sun2, Yuchi Han3, Hong Liu1, Dan Yang1, Weihao Li1, Jie Wang1, Wei Cheng2, Qing Zhang1, Zhi Zeng1, Yucheng Chen1.   

Abstract

BACKGROUND: Late gadolinium enhancement (LGE) pattern is a powerful imaging biomarker for prognosis of cardiac amyloidosis. It is unknown if the query amyloid late enhancement (QALE) score in light-chain (AL) amyloidosis could provide increased prognostic value compared with LGE pattern.Methods and 
Results: Seventy-eight consecutive patients with AL amyloidosis underwent contrast-enhanced cardiovascular magnetic resonance imaging. Patients with cardiac involvement were grouped by LGE pattern and analyzed using QALE score. Receiver operating characteristic curve was used to identify the optimal cut-off for QALE score in predicting all-cause mortality. Survival of these patients was analyzed with the Kaplan-Meier method and multivariate Cox regression. During a median follow-up of 34 months, 53 of 78 patients died. The optimal cut-off for QALE score to predict mortality at 12-month follow-up was 9.0. On multivariate Cox analysis, QALE score ≥9 (HR, 5.997; 95% CI: 2.665-13.497; P<0.001) and log N-terminal pro-brain natriuretic peptide (HR, 1.525; 95% CI: 1.112-2.092; P=0.009) were the only 2 independent predictors of all-cause mortality. On Kaplan-Meier analysis, patients with subendocardial LGE can be further risk stratified using QALE score ≥9.
CONCLUSIONS: The QALE scoring system provides powerful independent prognostic value in AL cardiac amyloidosis. QALE score ≥9 has added value to differentiate prognosis in AL amyloidosis patients with a subendocardial LGE pattern.

Entities:  

Keywords:  Late gadolinium enhancement; Light-chain amyloidosis; Mortality; Query amyloid late enhancement score

Mesh:

Substances:

Year:  2017        PMID: 29093431     DOI: 10.1253/circj.CJ-17-0464

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  4 in total

1.  Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis.

Authors:  Nisha Arenja; Florian Andre; Johannes H Riffel; Fabian Aus dem Siepen; Ute Hegenbart; Stefan Schönland; Arnt V Kristen; Hugo A Katus; Sebastian J Buss
Journal:  J Cardiovasc Magn Reson       Date:  2019-08-22       Impact factor: 5.364

2.  Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.

Authors:  Faye A Sharpley; Marianna Fontana; Ana Martinez-Naharro; Richa Manwani; Shameem Mahmood; Sajitha Sachchithanantham; Helen J Lachmann; Julian D Gillmore; Carol J Whelan; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Haematologica       Date:  2019-08-08       Impact factor: 9.941

Review 3.  Multimodality Imaging in the Diagnosis and Assessment of Cardiac Amyloidosis.

Authors:  Jyothirmayi Velaga; Charlene Liew; Angeline Choo Choo Poh; Phong Teck Lee; Narayan Lath; Shoen Choon Low; Pushan Bharadwaj
Journal:  World J Nucl Med       Date:  2022-08-16

Review 4.  The Role of Multi-modality Imaging in the Diagnosis of Cardiac Amyloidosis: A Focused Update.

Authors:  Shaun Khanna; Ivy Wen; Aditya Bhat; Henry H L Chen; Gary C H Gan; Faraz Pathan; Timothy C Tan
Journal:  Front Cardiovasc Med       Date:  2020-10-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.